Glytech, Inc   Report issue

For profit Phase 3
Founded: Kyoto Japan (2012)
Status: No NME R&D (2012)

Organization Overview

First Clinical Trial
None
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2006

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

glycine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Schizophrenia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1